Genelux Corp
Research Genelux Corp (GNLX) on Bullrun: market cap USD 122.68M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGNLX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 122.68M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 8.93M
- Free cash flow-USD 27.88M
Valuation Snapshot
latest market cap is USD 122.68M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 8.00K | -USD 32.15M | -USD 26.37M | n/a | -0.86 | USD 5.33M | USD 1.69M | USD 11.54M |
| FY2024 | USD 8.00K | -USD 29.87M | -USD 21.61M | n/a | -0.95 | USD 8.57M | USD 1.87M | USD 26.27M |
| FY2023 | USD 170.00K | -USD 28.30M | -USD 21.30M | n/a | -1.16 | USD 9.42M | USD 900.00K | USD 19.47M |
| FY2022 | USD 11.07M | -USD 5.21M | -USD 3.62M | n/a | -0.57 | USD 397.00K | USD 25.47M | -USD 35.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 122.68M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 166.29M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 81.96M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 374.31M | n/a | n/a | n/a |
About Genelux Corp
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Genelux Corp's market cap?
Genelux Corp's market capitalization is USD 122.68M.
What does Genelux Corp do?
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.